

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ABX-PHRI CONAPPLN. NO.  
10/628,004INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Abraham Pinter et al.CONFIRMATION NO.  
3975FILING DATE  
July 25, 2003GROUP  
1645

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MH	5,266,478	11/30/1993	Chang et al.	435	240.27	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
MH	WO 95/24904	09/21/1995	PCT				
MH	WO 96/34096	10/31/1996	PCT				
MH	WO 99/12556	3/18/1999	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
MH	Alsmadi, O. et al., "Antibody-Dependent Cellular Cytotoxicity Directed against Cells Expressing Human Immunodeficiency Virus Type 1 Envelope of Primary or Laboratory-Adapted Strains by Human and Chimpanzee Monoclonal Antibodies of Different Epitope Specificities," <i>J. Virol.</i> , 72:286-293 (1998)
	Arendrup, M. et al., "The HIV-1 V3 Domain on Field Isolates: Participation in Generation of Escape Virus In Vivo and Accessibility to Neutralizing Antibodies," <i>Arch Virol</i> , 140:655-670 (1995)
	Arendrup, M. et al., "Neutralizing Antibody Response During Human Immunodeficiency Virus Type 1 Infection: Type and Group Specificity and Viral Escape," <i>Journal of General Virology</i> , 74:855-863 (1993)
	Barbas, C.F. et al., "Molecular Profile of an Antibody Response to HIV-1 as Probed by Combinatorial Libraries," <i>J. Mol. Biol.</i> , 230:812-823 (1993)
	Berger, E.A. et al., "Chemokine Receptors As HIV-1 Coreceptors: Roles in Viral Entry, Tropism, and Disease," <i>Annual Reviews Immunol.</i> , 17:657-700 (1999).
	Berman, P.W. et al., "Genetic and Immunologic Characterization of Viruses Infecting MN-rgp 120-Vaccinated Volunteers," <i>The Journal of Infectious Diseases</i> , 176:384-397 (1997)
	Binley, J.M. et al., "An Investigation of the High-Avidity Antibody Response to Glycoprotein 120 of Human Immunodeficiency Virus Type 1," <i>AIDS Research and Human Retroviruses</i> , 13:1007-1015 (1997)
	Boots, L.J. et al., "Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries," <i>AIDS Research and Human Retroviruses</i> , 13:1549-1559 (1997)
	Conley, A.J. et al., "Neutralization of Primary Human Immunodeficiency Virus Type 1 Isolates by the Broadly Reactive Anti-V3 Monoclonal Antibody, 447-52D," <i>J. Virol.</i> , 68:6994-7000 (1994)
	Conley, A.J. et al., "Neutralization of Divergent Human Immunodeficiency Virus Type 1 Variants and Primary Isolates by IAM-41-2F5, an Anti-gp41 Human Monoclonal Antibody," <i>Proc. Natl. Acad. Sci.</i> , 91:3348-3352 (1994)

EXAMINER


/Myron Hill/

DATE CONSIDERED

12/09/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ABX-PHRI CONAPPLN. NO.  
10/628,004INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Abraham Pinter et al.CONFIRMATION NO.  
3975FILING DATE  
July 25, 2003GROUP  
1645

MH	Ditzel, H.J. et al., "Mapping the Protein Surface of Human Immunodeficiency Virus Type 1 gp120 using Human Monoclonal Antibodies from Phage Display Libraries," <i>J. Mol. Biol.</i> , 267:684-695 (1997).
	D'Souza, P.M. et al., "Evaluation of Monoclonal Antibodies to HIV-1 by Neutralization and Serological Assays: an International Collaboration," <i>AIDS</i> , 5:1061-1070 (1991)
	D'Souza, P.M. et al., "Neutralization of Primary HIV-1 Isolates by Anti-Envelope Monoclonal Antibodies," <i>AIDS</i> , 9:867-874 (1995)
	D'Souza, P.M. et al., "Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials," <i>The Journal of Infectious Diseases</i> , 175:1056-1062 (1997)
	Fontenot, J.D. et al., "Presentation of HIV V3 Loop Epitopes for Enhanced Antigenicity, Immunogenicity and Diagnostic Potential," <i>AIDS</i> , 9:1121-1129 (1995)
	Forthal, D.N. et al., "Functional Activities of 20 Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Human Monoclonal Antibodies," <i>AIDS Research and Human Retroviruses</i> , 11:1095-1099 (1995)
	Fouts, T.R. et al., "Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope Glycoprotein Complex," <i>J. Virol.</i> , 71:2779-2785 (1997)
	Fung, M.S. C. et al., "Identification and Characterization of a Neutralization Site Within the Second Variable Region of Human Immunodeficiency Virus Type 1 gp120," <i>J. Virol.</i> , 66:848-856 (1992)
	Gauduin, M.-C. et al., "Effective Ex Vivo Neutralization of Human Immunodeficiency Virus Type 1 in Plasma by Recombinant Immunoglobulin Molecules," <i>J. Virol.</i> , 70:2586-2592 (1996)
	Gorny, M.K. et al., "Production of Site-Selected Neutralizing Human Monoclonal Antibodies against the Third Variable Domain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein," <i>Proc. Natl. Acad. Sci.</i> , 88:3238-3242 (1991)
	Gorny, M. K. et al., "Repertoire of Neutralizing Human Monoclonal Antibodies Specific for the V3 Domain of HIV-1 gp120," <i>J. Immunol.</i> , 150:635-643 (1993)
	Gorny, M.K. et al., "Human Anti-V2 Monoclonal Antibody that Neutralizes Primary but not Laboratory Isolates of Human Immunodeficiency Virus Type 1," <i>J. Virol.</i> , 68:8312-8320 (1994)
	Gorny, M.K., "Human Monoclonal Antibodies to the V3 Loop of HIV-1 With Intra- and Interclade Cross-Reactivity," <i>J. Immunol.</i> , 159: 5114-5122 (1997).
	Gorny, M.K. et al., "A Human Monoclonal Antibody Specific for the V3 Loop of HIV Type 1 Clade E Cross-React with Other HIV Type 1 Clades," <i>AIDS Research and Human Retroviruses</i> , 14:213-221 (1998).
	He, Y. et al., "Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci," <i>J. Immunol.</i> , 169:595-605 (2002).
	Hill, M.C. et al., "Envelope Glycoproteins from Human Immunodeficiency Virus Types 1 and 2 and Simian Immunodeficiency Virus Can Use Human CCR5 as a Coreceptor for Viral Entry and Make Direct CD4-Dependent Interactions with This Chemokine Receptor," <i>J. Virol.</i> , 71:6296-6304 (1997)
	Karwowska, S. et al., "'Type-Specific' Human Monoclonal Antibodies Cross-React with the V3 Loop of Various HIV-1 Isolates," <i>Vaccines</i> 92, 171-174 (1992)
↓	Kayman, S.C. et al., "Presentation of Native Epitopes in the V1/V2 and V3 Regions of Human Immunodeficiency Virus Type 1 gp120 by Fusion Glycoproteins Containing Isolated gp120 Domains," <i>J. Virol.</i> , 68:400-410 (1994).

EXAMINER


/Myron Hill/

DATE CONSIDERED

12/09/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ABX-PHRI CONAPPLN. NO.  
10/628,004INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Abraham Pinter et al.CONFIRMATION NO.  
3975FILING DATE  
July 25, 2003GROUP  
1645

MH	Krachmarov, C.P. et al., "V-3 Specific Polyclonal Antibodies Affinity Purified from Sera of Infected Humans Effectively Neutralize Primary Isolates of Human Immunodeficiency Virus Type 1," <i>AIDS Research and Human Retroviruses</i> , 17:1737-1748 (2001).
	LaCasse, R.A. et al., "Fusion-Competent Vaccines: Broad Neutralization of Primary Isolates of HIV," <i>Science</i> , 283:357-362 (1999)
	Laisney, I.L. et al., "Dual Specificity of a Human Neutralizing Monoclonal Antibody, Specific for the V3 Loop of GP120 (HIV-1)," <i>Immunology Letters</i> , 67:185-192 (1999)
	Little, M. et al., "Of Mice and Men: Hybridoma and Recombinant Antibodies," <i>Immunology Today</i> , 21:364-370 (2000).
	McKeating, J.A. et al., "Chimeric Viruses Expressing Primary Envelope Glycoproteins of Human Immunodeficiency Virus Type 1 Show Increased Sensitivity to Neutralization by Human Sera," <i>Virology</i> , 220:450-460 (1996)
	Mondor, I. et al., "Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans," <i>J. Virol.</i> , 72:3623-3634 (1998)
	Moore, J.P. et al., "Immunochemical Analysis of the gp120 Surface Glycoprotein of Human Immunodeficiency Virus Type 1: Probing the Structure of the C4 and V4 Domains and the Interaction of the C4 Domain with the V3 Loop," <i>J. Virol.</i> , 67:4785-4796 (1993)
	Moore, J.P. et al., "Probing the Structure of the V2 Domain of Human Immunodeficiency Virus Type 1 Surface Glycoprotein gp120 with a Panel of Eight Monoclonal Antibodies: Human Immune Response to the V1 and V2 Domains," <i>J. Virol.</i> , 67:6136-6151 (1993)
	Moore, J.P. et al., "Development of the Anti-gp120 Antibody Response During Seroconversion to Human Immunodeficiency Virus Type 1," <i>J. Virol.</i> , 68:5142-5155 (1994)
	Moore, J.P. et al., "Exploration of Antigenic Variation in gp120 From Clades A Through F of Human Immunodeficiency Virus Type 1 by Using Monoclonal Antibodies," <i>J. Virol.</i> , 68:8350-8364 (1994)
	Moore, J.P. et al., "HIV-1 Neutralization: the Consequence of Viral Adaptation to Growth on Transformed T Cells," <i>AIDS</i> , 9:S117-S136 (1995)
	Moore, J.P. et al., "A Human Monoclonal Antibody to a Complex Epitope in the V3 Region of gp120 of Human Immunodeficiency Virus Type 1 Has Broad Reactivity Within and Outside Clade B," <i>J. Virol.</i> , 69:122-130 (1995)
	Moore, John P. et al., "Antibody Cross-Competition Analysis of the Human Immunodeficiency Virus Type 1 gp120 Exterior Envelope Glycoprotein," <i>J. Virol.</i> , 70:1863-1872 (1996)
	Murakami, T. et al., "Inhibitory Mechanism of the CXCR4 Antagonist T22 against Human Immunodeficiency Virus Type 1 Infection," <i>J. Virol.</i> , 73:7489-7496 (1999)
	Nyambi, P.N. et al., "Mapping of Epitopes Exposed on Intact Human Immunodeficiency Virus Type 1 (HIV-1) Virions: a New Strategy for Studying the Immunologic Relatedness of HIV-1," <i>J. Virol.</i> , 72:9384-9391 (1998)
	Pal, R. et al., "Characterization of a Neutralizing Monoclonal Antibody to the External Glycoprotein of HIV-1," <i>Intervirology</i> , 86:86-93 (1992)
	Parren, P.W. H. et al., "Antibodies against HIV-1 from Phage Display Libraries: Mapping of an Immune Response and Progress Towards Antiviral Immunotherapy," <i>Chemical Immunology</i> , 65:18-56 (1997)
↓	Parren, P.W. H. et al., "Erratum to 'Relevance of the Antibody Response Against Human Immunodeficiency Virus Type 1 Envelope to Vaccine Design'," <i>Immunology Letters</i> , 58:125-132 (1997)

EXAMINER

DATE CONSIDERED

/Myron Hill/

12/09/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ABX-PHRI CONAPPLN. NO.  
10/628,004INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Abraham Pinter et al.CONFIRMATION NO.  
3975FILING DATE  
July 25, 2003GROUP  
1645

MH	Parren, P.W. H. et al., "Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity," <i>J. Virol.</i> , 72:3512-3519 (1998)
	Pinter, A. et al., "A Potent, Neutralizing Human Monoclonal Antibody Against a Unique Epitope Overlapping the CD4 Binding Site of HIV-1 gp120 That is Broadly Conserved Across North American and African Virus Isolates," <i>AIDS Research and Human Retroviruses</i> , 9:985-996 (1993)
	Pinter, A. et al., "Potent Neutralization of Primary HIV-1 Isolates by Antibodies Directed Against Epitopes Present in the V1/V2 Domain of HIV-1 gp120," <i>Vaccine</i> , 16:1803-1811 (1998).
	Robinson, J.E. et al., "Identification of Conserved and Variant Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 by Human Monoclonal Antibodies Produced by EBV-Transformed Cell Lines," <i>AIDS Research and Human Retroviruses</i> , 6:567-579 (1990)
	Sattentau, Q.J., "Conservation of HIV-1 gp120 Neutralizing Epitopes After Formalin Inactivation," <i>AIDS</i> , 9:1383-1385 (1995)
	Schnierle, B.S. et al., "Pseudotyping of Murine Leukemia Virus with the Envelope Glycoproteins of HIV Generates a Retroviral Vector with Specificity of Infection for CD4-Expressing Cells," <i>Proc. Natl. Acad. Sci.</i> , 94:8640-8645 (1997)
	Schutten, M. et al., "Characterization of a V3 Domain-Specific Neutralizing Human Monoclonal Antibody that Preferentially Recognizes Non-Syncytium-Inducing Human Immunodeficiency Virus Type 1 Strains," <i>Journal of General Virology</i> , 76:1665-1673 (1995)
	Schutten, M. et al., "Enhancement of Infectivity of a Non-Syncytium Inducing HIV-1 by sCD4 and by Human Antibodies that Neutralize Syncytium-Inducing HIV-1," <i>Scand. J. Immunol.</i> , 41:18-22 (1995)
	Schutten, M. et al., "Human Antibodies that Neutralize Primary Human Immunodeficiency Virus Type 1 <i>in vitro</i> Do Not Provide Protection in an <i>in vivo</i> Model," <i>Journal of General Virology</i> , 77:1667-1675 (1996)
	Schutten, M. et al., "Modulation of Primary Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Entry by Human Antibodies," <i>Journal of General Virology</i> , 78:999-1006 (1997)
	Scott, C.F. et al., "Human Monoclonal Antibody That Recognizes the V3 Region of Human Immunodeficiency Virus gp120 and Neutralizes the Human T-Lymphotropic Virus Type III <sub>MN</sub> Strain," <i>Proc. Natl. Acad. Sci.</i> , 87:8597-8601 (1990)
	Seligman, S.J. et al., "Characterization by Serial Deletion Competition ELISAs of HIV-1 V3 Loop Epitopes Recognized by Monoclonal Antibodies," <i>Molecular Immunology</i> , 33:737-745 (1996)
	Stamatatos, L. et al., "An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades," <i>J. Virol.</i> , 72:7840-7845 (1998)
	Sullivan, N. et al., "Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies," <i>J. Virol.</i> , 72:6332-6338 (1998)
	Thall, M. et al., "Characterization of Conserved Human Immunodeficiency Virus Type 1 gp120 Neutralization Epitopes Exposed Upon gp120-CD4 Binding," <i>J. Virol.</i> , 67:3978-3988 (1993)
	Tilley, S.A. et al., "Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120," <i>AIDS Research and Human Retroviruses</i> , 8:461-467 (1992).
	Trkola, A. et al., "Cross-Clade Neutralization of Primary Isolates of Human Immunodeficiency Virus Type 1 by Human Monoclonal Antibodies and Tetrameric CD4-IgG," <i>J. Virol.</i> , 69:6609-6617 (1995)

EXAMINER

/Myron Hill/

DATE CONSIDERED

12/09/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ABX-PHRI CONAPPLN. NO.  
10/628,004INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Abraham Pinter et al.CONFIRMATION NO.  
3975FILING DATE  
July 25, 2003GROUP  
1645

MH	Trkola, A. et al., "CD4-Dependent, Antibody-Sensitive Interactions Between HIV-1 and Its Co-receptor CCR-5," <i>Nature</i> , 384:184-187 (1996)
	Trkola, A. et al., "Human Monoclonal Antibody 2G12 Defines a Distinctive Neutralization Epitope on the gp120 Glycoprotein of Human Immunodeficiency Virus Type 1," <i>J. Virol.</i> , 70:1100-1108 (1996)
	Tykola, A. et al., "Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage," <i>J. Virol.</i> , 72:1876-1885 (1998)
	Ugolini, S. et al., "Inhibition of Virus Attachment to CD4 <sup>+</sup> Target Cells Is a Major Mechanism of T Cell Line-Adapted HIV-1 Neutralization," <i>J. Exp. Med.</i> , 186:1287-1298 (1997)
	VanCott, T.C. et al., "Dissociation Rate of Antibody-gp120 Binding Interactions Is Predictive of V3-Mediated Neutralization of HIV-1," <i>J. Immunol.</i> , 153:449-459 (1994)
	van Spriël, A.B., "Immunotherapeutic Perspective for Bispecific Antibodies," <i>Immunology Today</i> , 21:391-397 (2000).
	Wu, D. et al., "Neuroprotection With Noninvasive Neurotrophin Delivery to the Brain," <i>Proc. Natl. Acad. Sci.</i> , 96:254-259 (1999).
	Wu, L. et al., "CD4-Induced Interaction of Primary HIV-1 gp120 Glycoproteins With the Chemokine Receptor CCR-5," <i>Nature</i> , 384:179-183 (1996)
	Yang, G. et al., "Neutralizing Antibodies Against HIV Determined by Amplification of Viral Long Terminal Repeat Sequences From Cells Infected in Vitro by Nonneutralized Virions," <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , 17:27-34 (1998)
	Zolla-Pazner, S. et al., "Neutralization of a Clade B Primary Isolate by Sera from Human Immunodeficiency Virus —Uninfected Recipients of Candidate AIDS Vaccines," <i>J. Infect. Diseases.</i> , 175:764-774 (1997)
↓	Zolla-Pazner, S. et al., "Immunotyping of Human Immunodeficiency Virus Type 1 (HIV): an Approach to Immunologic Classification of HIV," <i>J. Virol.</i> , 73:4042-4051 (1999)

EXAMINER /Myron Hill/

DATE CONSIDERED

12/09/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.